Exscientia plc (NASDAQ:EXAI) Q1 2024 Earnings Conference Call May 21, 2024 8:30 AM ET
Company Participants
Chinedu Okeke - Associate Director-Strategy, IR
David Hallett - Interim CEO, Chief Scientific Officer
Ben Taylor - CFO, Chief Strategy Officer
Conference Call Participants
Alec Stranahan - Bank of America
Vikram Purohit - Morgan Stanley
Peter Lawson - Barclays
Operator
Hello, everyone. My name is Sarah, and I will be your conference operator today. At this time, I would like to welcome everyone to Exscientias' Business Update Call for the First Quarter 2024. All line have been placed on mute to prevent any background noise. After the speakers remarks there will be a question-and-answer session.
At this time, I would like to introduce Chin Okeke, Associate Director of Strategy and Investor Relations. Chin, you may begin.
Chinedu Okeke
Thank you, operator, and welcome, everyone, to Exscientia's First Quarter 2024 Financial Results and Business Update Conference Call. A press release and 6-K were issued this morning with our first quarter 2024 financial results and business update. These documents can be found on our website at investors.exscientia.ai, along with the presentation for today's webcast.
Before we begin, I'd like to remind you that we may make forward-looking statements on our call. These may include statements about our projected growth, revenue, business models, preclinical and clinical progress and results, and business activities and performance as well as our anticipated cash runway. Actual results may differ materially from those indicated by these statements. Unless required by law, Exscientia does not undertake any obligation to update these statements regarding the future or to confirm these statements in relation to actual results.
On today's call, I'm joined by Dr. Dave Hallett, Interim Chief Executive Officer and Chief Scientific Officer; and Ben Taylor, Chief Financial Officer and Chief Strategy Officer. And with that, I will now turn the call over to Dave.
David Hallett
Thank you, Chin. While the first quarter of 2024 has been my first officially leading Exscientia, the turn of the year marked the beginning of my fifth year as a senior executive at the company. With this experience and perspective in mind, I firmly believe that 2024 will be a year of opportunity for Exscientia to continue making substantial progress on our mission to shift the curve of the pharmaceutical industry.
The tangible benefits of our investment in platform and infrastructure are gaining pace. When we at Exscientia refer to shifting the curve, we are referring to reducing the cost and timelines of contemporary drug discovery, design and development, while also increasing the probability of success. We have already demonstrated a repeated ability to lower the cost and time in the discovery phase of drug design projects.